QI & Technicals in View For WestRock Company (NYSE:WRK), Sarepta Therapeutics, Inc. (NasdaqGS:SRPT)

The Q.i. Value ranks companies using four ratios. These ratios consist of EBITDA Yield, FCF Yield, Liquidity, and Earnings Yield. The purpose of the Q.i. Value is to help identify companies that are the most undervalued. Typically, the lower the value, the more undervalued the company tends to be. WestRock Company (NYSE:WRK) currently has a Q.i. Value of 13.00000.

Investors often have to decide how aggressive they are going to be in the stock market. Having the mindset of getting rich quick may result in the rapid loss of capital. Of course, there are those who have possibly had luck on their side, but jumping in head first without a plan can be a recipe for disaster. It may be tempting to take a leap with a risky stock. However, high returns in the equity market may come with extensive risk and volatility. Managing that risk in turbulent markets may help keep the average investor above water when things swing the wrong way. Investors may want to assess if they are trading too much or trading the wrong types of stocks. Doing all the research may involve keeping a close tab on technicals, fundamentals, relevant economic data, and earnings reports. Investors may have to find a way to keep the rational side from being consumed by irrational behavior when analyzing the markets.

We can now take a quick look at some historical stock price index data. WestRock Company (NYSE:WRK) presently has a 10 month price index of 0.65929. The price index is calculated by dividing the current share price by the share price ten months ago. A ratio over one indicates an increase in share price over the period. A ratio lower than one shows that the price has decreased over that time period.

Looking at some alternate time periods, the 12 month price index is 0.62413, the 24 month is 0.87354, and the 36 month is 1.27043. Narrowing in a bit closer, the 5 month price index is 0.75315, the 3 month is 0.98576, and the 1 month is currently 1.05234.

WestRock Company (NYSE:WRK) has a current ERP5 Rank of 3380. The ERP5 Rank may assist investors with spotting companies that are undervalued. This ranking uses four ratios. These ratios are Earnings Yield, ROIC, Price to Book, and 5 year average ROIC. When looking at the ERP5 ranking, it is generally considered the lower the value, the better.

Checking in on some valuation rankings, WestRock Company (NYSE:WRK) has a Value Composite score of 6. Developed by James O’Shaughnessy, the VC score uses five valuation ratios. These ratios are price to earnings, price to cash flow, EBITDA to EV, price to book value, and price to sales. The VC is displayed as a number between 1 and 100. In general, a company with a score closer to 0 would be seen as undervalued, and a score closer to 100 would indicate an overvalued company. Adding a sixth ratio, shareholder yield, we can view the Value Composite 2 score which is currently sitting at 4.

Watching some historical volatility numbers on shares of WestRock Company (NYSE:WRK), we can see that the 12 month volatility is presently 34.383300. The 6 month volatility is 33.607100, and the 3 month is spotted at 40.172000. Following volatility data can help measure how much the stock price has fluctuated over the specified time period. Although past volatility action may help project future stock volatility, it may also be vastly different when taking into account other factors that may be driving price action during the measured time period.

Current Ratio

The Current Ratio of WestRock Company (NYSE:WRK) is 1.44. The Current Ratio is used by investors to determine whether a company can pay short term and long term debts. The current ratio looks at all the liquid and non-liquid assets compared to the company’s total current liabilities. A high current ratio indicates that the company might have trouble managing their working capital. A low current ratio (when the current liabilities are higher than the current assets) indicates that the company may have trouble paying their short term obligations.

Gross Margin Score

The Gross Margin Score is calculated by looking at the Gross Margin and the overall stability of the company over the course of 8 years. The score is a number between one and one hundred (1 being best and 100 being the worst). The Gross Margin Score of WestRock Company (NYSE:WRK) is 20.00000. The more stable the company, the lower the score. If a company is less stable over the course of time, they will have a higher score.

M-Score (Beneish)

The M-Score, conceived by accounting professor Messod Beneish, is a model for detecting whether a company has manipulated their earnings numbers or not. WestRock Company (NYSE:WRK) has an M-Score of -2.575598. The M-Score is based on 8 different variables: Days’ sales in receivables index, Gross Margin Index, Asset Quality Index, Sales Growth Index, Depreciation Index, Sales, General and Administrative expenses Index, Leverage Index and Total Accruals to Total Assets. A score higher than -1.78 is an indicator that the company might be manipulating their numbers.

Piotroski F-Score

The Piotroski F-Score is a scoring system between 1-9 that determines a firm’s financial strength. The score helps determine if a company’s stock is valuable or not. The Piotroski F-Score of WestRock Company (NYSE:WRK) is 7. A score of nine indicates a high value stock, while a score of one indicates a low value stock. The score is calculated by the return on assets (ROA), Cash flow return on assets (CFROA), change in return of assets, and quality of earnings. It is also calculated by a change in gearing or leverage, liquidity, and change in shares in issue. The score is also determined by change in gross margin and change in asset turnover.

Trying to project the day to day short-term movements of the stock market may be all but impossible. Stocks have the tendency to make sudden moves on even the slightest bit of news or for apparently no reason at all. The daily trader may be looking to capitalize on swings or momentum, but the long-term investor may be searching for stability and consistency over a sustained period of time. During trading sessions, stock movements can seem like a popularity contest from time to time. Even after careful study, there may be no logical reason for a particular stock move. Riding out the waves of uncertainty may not be easy, but having a full-proof plan for when markets erode may just be the savior. Having the patience to wait out abnormal moves may help evade the mistake of letting go too soon out of panic. 

Sarepta Therapeutics, Inc. (NasdaqGS:SRPT) has a Q.i. Value of 65.00000. The purpose of the Q.i. Value is to help identify companies that are the most undervalued. Typically, the lower the value, the more undervalued the company tends to be. The Q.i. Value ranks companies using four ratios. These ratios consist of EBITDA Yield, FCF Yield, Liquidity, and Earnings Yield. 

Investors may be getting ready to buy into the stock market as we cruise into the second half of the year. Filtering out the constant noise in the markets can be challenging. Sifting through all the data can be trying, especially for the novice investor. Digging down into the fundamentals may help weed out the undesirable companies. Investors will most likely be scouting out the equity market for any bargains. Although they may be harder to find these days, there still may be a hidden gem out there somewhere. As companies start to report quarterly earnings, investors will be closely following to see which ones are poised for success over the next few quarters.  

Checking in on some valuation rankings, Sarepta Therapeutics, Inc. (NasdaqGS:SRPT) has a Value Composite score of 87. Developed by James O’Shaughnessy, the VC score uses five valuation ratios. These ratios are price to earnings, price to cash flow, EBITDA to EV, price to book value, and price to sales.

The VC is displayed as a number between 1 and 100. In general, a company with a score closer to 0 would be seen as undervalued, and a score closer to 100 would indicate an overvalued company. Adding a sixth ratio, shareholder yield, we can view the Value Composite 2 score which is currently sitting at 86.

Following volatility data can help measure how much the stock price has fluctuated over the specified time period. Although past volatility action may help project future stock volatility, it may also be vastly different when taking into account other factors that may be driving price action during the measured time period.

We can now take a quick look at some historical stock price index data. Sarepta Therapeutics, Inc. (NasdaqGS:SRPT) presently has a 10 month price index of 1.55877. The price index is calculated by dividing the current share price by the share price ten months ago. A ratio over one indicates an increase in share price over the period. A ratio lower than one shows that the price has decreased over that time period.

Sarepta Therapeutics, Inc. (NasdaqGS:SRPT) has a current ERP5 Rank of 16581. The ERP5 Rank may assist investors with spotting companies that are undervalued. This ranking uses four ratios. These ratios are Earnings Yield, ROIC, Price to Book, and 5 year average ROIC. When looking at the ERP5 ranking, it is generally considered the lower the value, the better.

Looking at some alternate time periods, the 12 month price index is 1.96858, the 24 month is 3.58750, and the 36 month is 9.13690. Narrowing in a bit closer, the 5 month price index is 0.96216, the 3 month is 0.91492, and the 1 month is currently 1.19096.

Watching some historical volatility numbers on shares of Sarepta Therapeutics, Inc. (NasdaqGS:SRPT), we can see that the 12 month volatility is presently 64.886900. The 6 month volatility is 54.800700, and the 3 month is spotted at 61.088900.

Key Ratios

Turning to some key ratios, Sarepta Therapeutics, Inc. (NasdaqGS:SRPT)’s Leverage Ratio was recently noted as 0.418968. This ratio is calculated by dividing total debt by total assets plus total assets previous year, divided by two. The leverage of a company is relative to the amount of debt on the balance sheet. This ratio is often viewed as one measure of the financial health of a firm.

Sarepta Therapeutics, Inc. (NasdaqGS:SRPT) presently has a current ratio of 8.85. The current ratio, also known as the working capital ratio, is a liquidity ratio that displays the proportion of current assets of a business relative to the current liabilities. The ratio is simply calculated by dividing current liabilities by current assets. The ratio may be used to provide an idea of the ability of a certain company to pay back its liabilities with assets. Typically, the higher the current ratio the better, as the company may be more capable of paying back its obligations.

The price to book ratio or market to book ratio for Sarepta Therapeutics, Inc. (NasdaqGS:SRPT) currently stands at 13.532386.  The ratio is calculated by dividing the stock price per share by the book value per share.  This ratio is used to determine how the market values the equity.  A ratio of under 1 typically indicates that the shares are undervalued.  A ratio over 1 indicates that the market is willing to pay more for the shares.  There are often many underlying factors that come into play with the Price to Book ratio so all additional metrics should be considered as well. 

Ever wonder how investors predict positive share price momentum?  The Cross SMA 50/200, also known as the “Golden Cross” is the fifty day moving average divided by the two hundred day moving average.  The SMA 50/200 for Sarepta Therapeutics, Inc. (NasdaqGS:SRPT) is currently 0.96936.  If the Golden Cross is greater than 1, then the 50 day moving average is above the 200 day moving average – indicating a positive share price momentum.  If the Golden Cross is less than 1, then the 50 day moving average is below the 200 day moving average, indicating that the price might drop.

C Score (Montier)

The C-Score is a system developed by James Montier that helps determine whether a company is involved in falsifying their financial statements. The C-Score is calculated by a variety of items, including a growing difference in net income verse cash flow, increasing days outstanding, growing days sales of inventory, increasing assets to sales, declines in depreciation, and high total asset growth. The C-Score of Sarepta Therapeutics, Inc. (NasdaqGS:SRPT) is 2.00000. The score ranges on a scale of -1 to 6. If the score is -1, then there is not enough information to determine the C-Score. If the number is at zero (0) then there is no evidence of fraudulent book cooking, whereas a number of 6 indicates a high likelihood of fraudulent activity. The C-Score assists investors in assessing the likelihood of a company cheating in the books.

Investors are constantly looking for ways to achieve success trading the stock market. Veteran investors may have spent many years trying to figure out the best way to build a winning stock portfolio. Unfortunately, there is no secret formula to beating the market. New investors may start trading with some preconceived notions about how to make money in stocks. Although there are some methods that might have worked in the past, nobody can guarantee future results based on past methods and performance. Investors may end up finding out the hard way that there is rarely any substitute for hard work and dedication, especially when picking stocks. 

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.